Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.
Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients.
Based on its pre-clinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
March 12, 2024
RegMed Investors (RMi) Closing Bell: fresh inflation “number” upset daily share pricing response
March 8, 2024
RegMed Investors (RMi) Closing Bell: a drop the mic (microphone) ending for the sector
March 1, 2024
RegMed Investors (RMi) Closing Bell: another knee-jerk reaction but, to our advantage
February 29, 2024
RegMed Investors (RMi) Closing Bell: investor jitters
February 28, 2024
RegMed Investors (RMi) Closing Bell: run from sector highs to cash as a portfolio value preservation strategy
February 27, 2024
RegMed Investors (RMi) Closing Bell: a rising tide
February 26, 2024
RegMed Investors (RMi) Closing Bell: bubblicious sentiment?
February 23, 2024
RegMed Investors (RMi) Closing Bell: yesterday’s ups and downs were switching positions
35 companies, 1 interpreter!
Insight, foresight and recommendation
Biostage (BSTG) - The implementation of this reverse stock split will continue CEO McGorry’s “abuse and destruction of the shareholder value due to his mismanagement, misdirection and misdeeds”. It’s all about salary and “bennies” continuance, violations of fiduciary omittance and having condoned and ignored employee – male and female harassment.” And if that isn’t enough … Is Biostage (BSTG) a Ponzi or Pyramid scheme or a combination of both …? A $300 K down payment and $4 M buys a shell from which $30 M was wasted and a $47 M deficit created …
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors